← All trials
NCT04994314
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 15, 2021
- Primary completion
- Dec 16, 2021
- Completion date
- Feb 15, 2022
- First posted
- Aug 6, 2021
- Last posted
- Aug 6, 2021
- Enrollment
- 31
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of BaghdadLead sponsor
- University of BaghdadReponsible party - principal investigator
- University of BaghdadStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.